Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope

Author(s): Gonzalo Recondo, Gonzalo Recondo, Fernando Galanternik, Martín Greco, Máximo de la Vega, E. Diaz Cantón, Matías E. Valsecchi.

Journal Name: Reviews on Recent Clinical Trials

Volume 11 , Issue 2 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Lung cancer is a major public health problem worldwide and the leading cause of cancerrelated mortality in developed countries. Significant advances have been made especially with the discovery of targeted agents. However, only a small proportion of patients carry activating mutations; until recently conventional chemotherapy and angiogenesis inhibitors were the preferred treatment for the vast majority of patients. Now, the successful experience of anti-PD-1 agents may have opened the door to a novel and previously unexplored dimension in the treatment of lung cancer: immunotherapy. In this mini-review we will discuss the current applications and future consequences related this topic, paying special attention to the clinical studies that constitute the scientific evidence to supports its use.

Keywords: Immunotherapy, lung cancer, nivolumab, PD-1, squamous cell carcinoma.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [87 - 92]
Pages: 6
DOI: 10.2174/1574887111666160330121349

Article Metrics

PDF: 36